25 Leading India Pharmas Spend Less Than Half Global Average On R&D
This article was originally published in PharmAsia News
India drug makers still trail the global average in spending on research and development as a percentage of total sales and even then record a low success rate in innovation attempts.
You may also be interested in...
Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.